3-Iodobenzylguanidine
The therapeutic efficacy of Iobenguane can be decreased when used in combination with Doxepin.
4-Hydroxybutyric Acid
The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Doxepin.
Abiraterone
The serum concentration of Doxepin can be increased when it is combined with Abiraterone.
Advertisement
Acenocoumarol
Doxepin may increase the anticoagulant activities of Acenocoumarol.
Acepromazine
The risk or severity of adverse effects can be increased when Doxepin is combined with Acepromazine.
Aceprometazine
The risk or severity of adverse effects can be increased when Doxepin is combined with Aceprometazine.
Advertisement
Acetophenazine
The risk or severity of adverse effects can be increased when Doxepin is combined with Acetophenazine.
Afatinib
The serum concentration of Afatinib can be increased when it is combined with Doxepin.
Albuterol
The risk or severity of adverse effects can be increased when Doxepin is combined with Salbutamol.
Advertisement
Alfaxalone
The risk or severity of adverse effects can be increased when Doxepin is combined with Alfaxalone.
Alfentanil
The risk or severity of adverse effects can be increased when Alfentanil is combined with Doxepin.
Almotriptan
The risk or severity of adverse effects can be increased when Almotriptan is combined with Doxepin.
Alogliptin
The serum concentration of Doxepin can be increased when it is combined with Alogliptin.
alpha 1-Antitrypsin
The serum concentration of Doxepin can be increased when it is combined with Alpha-1-proteinase inhibitor.
Alpha 1-Proteinase Inhibitor, Human
The serum concentration of Doxepin can be increased when it is combined with Alpha-1-proteinase inhibitor.
Alphaprodine
The risk or severity of adverse effects can be increased when Doxepin is combined with Alphaprodine.
Alprazolam
The risk or severity of adverse effects can be increased when Alprazolam is combined with Doxepin.
Altretamine
Altretamine may increase the orthostatic hypotensive activities of Doxepin.
Amiodarone
The metabolism of Doxepin can be decreased when combined with Amiodarone.
Amisulpride
The risk or severity of adverse effects can be increased when Doxepin is combined with Amisulpride.
Amitriptyline
The risk or severity of adverse effects can be increased when Amitriptyline is combined with Doxepin.
Amobarbital
The metabolism of Doxepin can be increased when combined with Amobarbital.
Amoxapine
The risk or severity of adverse effects can be increased when Amoxapine is combined with Doxepin.
Amphetamine
Amphetamine may decrease the sedative activities of Doxepin.
Amprenavir
The serum concentration of Doxepin can be increased when it is combined with Amprenavir.
Anagrelide
Doxepin may increase the QTc-prolonging activities of Anagrelide.
Antithrombin III
The serum concentration of Doxepin can be increased when it is combined with Antithrombin III human.
Antithrombin III, Human
The serum concentration of Doxepin can be increased when it is combined with Antithrombin III human.
Apalutamide
The serum concentration of Doxepin can be decreased when it is combined with Apalutamide.
Apixaban
The serum concentration of Doxepin can be increased when it is combined with Apixaban.
Apomorphine
Doxepin may decrease the antihypertensive activities of Apomorphine.
Apraclonidine
Doxepin may decrease the antihypertensive activities of Apraclonidine.
Aprepitant
The serum concentration of Doxepin can be increased when it is combined with Aprepitant.
Aprotinin
The serum concentration of Doxepin can be increased when it is combined with Aprotinin.
Arbutamine
The risk or severity of adverse effects can be increased when Doxepin is combined with Arbutamine.
Arformoterol
The risk or severity of adverse effects can be increased when Doxepin is combined with Arformoterol.
Argatroban
The serum concentration of Doxepin can be increased when it is combined with Argatroban.
Argatroban Anhydrous
The serum concentration of Doxepin can be increased when it is combined with Argatroban.
Aripiprazole
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Doxepin.
Armodafinil
The metabolism of Doxepin can be decreased when combined with Armodafinil.
Arsenic Trioxide
Doxepin may increase the QTc-prolonging activities of Arsenic trioxide.
Artemether
Doxepin may increase the QTc-prolonging activities of Artemether.
Articaine
The risk or severity of adverse effects can be increased when Doxepin is combined with Articaine.
Asenapine
Doxepin may increase the QTc-prolonging activities of Asenapine.
Asunaprevir
The serum concentration of Doxepin can be increased when it is combined with Asunaprevir.
Atazanavir
The serum concentration of Atazanavir can be decreased when it is combined with Doxepin.
Atomoxetine
The metabolism of Doxepin can be decreased when combined with Atomoxetine.
Azelastine
Doxepin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Azithromycin
The metabolism of Doxepin can be decreased when combined with Azithromycin.
Baclofen
The risk or severity of adverse effects can be increased when Baclofen is combined with Doxepin.
Bambuterol
The risk or severity of adverse effects can be increased when Doxepin is combined with Bambuterol.
Barbexaclone
The metabolism of Doxepin can be increased when combined with Barbexaclone.
Barbital
The metabolism of Doxepin can be increased when combined with Barbital.
Bedaquiline
Doxepin may increase the QTc-prolonging activities of Bedaquiline.
Benazepril
The serum concentration of Doxepin can be increased when it is combined with Benazepril.
Benoxinate
The risk or severity of adverse effects can be increased when Doxepin is combined with Oxybuprocaine.
Benperidol
The risk or severity of adverse effects can be increased when Doxepin is combined with Benperidol.
Benzocaine
The risk or severity of adverse effects can be increased when Doxepin is combined with Benzocaine.
Benzphetamine
Doxepin may decrease the antihypertensive activities of Benzphetamine.
Benzyl Alcohol
The risk or severity of adverse effects can be increased when Doxepin is combined with Benzyl alcohol.
Benzylpenicilloyl polylysine
Doxepin may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BETAHISTINE
The therapeutic efficacy of Betahistine can be decreased when used in combination with Doxepin.
Betaxolol
The metabolism of Doxepin can be decreased when combined with Betaxolol.
Bethanidine
Doxepin may decrease the antihypertensive activities of Bethanidine.
Bivalirudin
The serum concentration of Doxepin can be increased when it is combined with Bivalirudin.
Boceprevir
The metabolism of Doxepin can be decreased when combined with Boceprevir.
Bortezomib
The metabolism of Doxepin can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Doxepin can be decreased when it is combined with Bosentan.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Doxepin.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Doxepin.
Brentuximab Vedotin
The serum concentration of Brentuximab vedotin can be increased when it is combined with Doxepin.
Brexpiprazole
The risk or severity of adverse effects can be increased when Doxepin is combined with Brexpiprazole.
Brimonidine
Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Bromazepam
The risk or severity of adverse effects can be increased when Bromazepam is combined with Doxepin.
Bromocriptine
Doxepin may decrease the antihypertensive activities of Bromocriptine.
Bromperidol
The risk or severity of adverse effects can be increased when Doxepin is combined with Bromperidol.
Brompheniramine
The risk or severity of adverse effects can be increased when Brompheniramine is combined with Doxepin.
Brotizolam
The risk or severity of adverse effects can be increased when Doxepin is combined with Brotizolam.
Bupivacaine
The risk or severity of adverse effects can be increased when Doxepin is combined with Bupivacaine.
Buprenorphine
Doxepin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Bupropion
The metabolism of Doxepin can be decreased when combined with Bupropion.
Buspirone
The risk or severity of adverse effects can be increased when Buspirone is combined with Doxepin.
Butabarbital
The risk or severity of adverse effects can be increased when Butabarbital is combined with Doxepin.
Butalbital
The risk or severity of adverse effects can be increased when Butalbital is combined with Doxepin.
Butamben
The risk or severity of adverse effects can be increased when Doxepin is combined with Butamben.
Butobarbital
The risk or severity of adverse effects can be increased when Doxepin is combined with Butethal.
Butorphanol
The risk or severity of adverse effects can be increased when Butorphanol is combined with Doxepin.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Doxepin.
Caffeine
The metabolism of Doxepin can be decreased when combined with Caffeine.
Capecitabine
The metabolism of Doxepin can be decreased when combined with Capecitabine.
Captopril
The serum concentration of Doxepin can be increased when it is combined with Captopril.
Carbamazepine
The metabolism of Doxepin can be increased when combined with Carbamazepine.
Carbinoxamine
The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Doxepin.
Cariprazine
The risk or severity of adverse effects can be increased when Doxepin is combined with Cariprazine.
Carisoprodol
The risk or severity of adverse effects can be increased when Carisoprodol is combined with Doxepin.
Cefditoren
The serum concentration of Cefditoren can be decreased when it is combined with Doxepin.
Cefpodoxime
Doxepin can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cefuroxime
Doxepin can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.
Celecoxib
The metabolism of Doxepin can be decreased when combined with Celecoxib.
Celiprolol
The risk or severity of adverse effects can be increased when Doxepin is combined with Celiprolol.
Ceritinib
The serum concentration of Doxepin can be increased when it is combined with Ceritinib.
Cetirizine
The risk or severity of adverse effects can be increased when Cetirizine is combined with Doxepin.
Chloral Hydrate
The risk or severity of adverse effects can be increased when Doxepin is combined with Chloral hydrate.
Chloramphenicol
The metabolism of Doxepin can be decreased when combined with Chloramphenicol.
Chlordiazepoxide
The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Doxepin.
Chlormethiazole
The risk or severity of adverse effects can be increased when Doxepin is combined with clomethiazole.
Chlormezanone
The risk or severity of adverse effects can be increased when Doxepin is combined with Chlormezanone.
Chloroprocaine
The risk or severity of adverse effects can be increased when Doxepin is combined with Chloroprocaine.
Chloroquine
The metabolism of Doxepin can be decreased when combined with Chloroquine.
Chlorpheniramine
The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Doxepin.
CHLORPHENIRAMINE POLISTIREX
The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Doxepin.
Chlorpromazine
The metabolism of Doxepin can be decreased when combined with Chlorpromazine.
Chlorprothixene
The risk or severity of adverse effects can be increased when Doxepin is combined with Chlorprothixene.
Chlorzoxazone
The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Doxepin.
Cholecalciferol
The metabolism of Doxepin can be decreased when combined with Cholecalciferol.
Cholesterol
The serum concentration of Doxepin can be increased when it is combined with Cholesterol.
Cilastatin
The serum concentration of Doxepin can be increased when it is combined with Cilastatin.
Cilazapril
The serum concentration of Doxepin can be increased when it is combined with Cilazapril.
Cimetidine
The metabolism of Doxepin can be decreased when combined with Cimetidine.
Cinacalcet
The serum concentration of Doxepin can be increased when it is combined with Cinacalcet.
Ciprofloxacin
Doxepin may increase the QTc-prolonging activities of Ciprofloxacin.
Cisapride
Doxepin may increase the QTc-prolonging activities of Cisapride.
Citalopram
The risk or severity of adverse effects can be increased when Doxepin is combined with Citalopram.
Clarithromycin
The metabolism of Doxepin can be decreased when combined with Clarithromycin.
Clemastine
The metabolism of Doxepin can be decreased when combined with Clemastine.
Clenbuterol
The risk or severity of adverse effects can be increased when Doxepin is combined with Clenbuterol.
Clidinium
The risk or severity of adverse effects can be increased when Clidinium is combined with Doxepin.
Clidinium bromide
The risk or severity of adverse effects can be increased when Clidinium is combined with Doxepin.
Clobazam
The metabolism of Doxepin can be decreased when combined with Clobazam.
Clomipramine
The risk or severity of adverse effects can be increased when Doxepin is combined with Clomipramine.
Clonazepam
The risk or severity of adverse effects can be increased when Clonazepam is combined with Doxepin.
Clonidine
Doxepin may decrease the antihypertensive activities of Clonidine.
Clorazepate
The risk or severity of adverse effects can be increased when Clorazepate is combined with Doxepin.
CLORAZEPIC ACID
The risk or severity of adverse effects can be increased when Clorazepate is combined with Doxepin.
Clotrimazole
The metabolism of Doxepin can be decreased when combined with Clotrimazole.
Clozapine
The metabolism of Doxepin can be decreased when combined with Clozapine.
Cobicistat
The serum concentration of Doxepin can be increased when it is combined with Cobicistat.
Cocaine
The metabolism of Doxepin can be decreased when combined with Cocaine.
Codeine
The risk or severity of adverse effects can be increased when Codeine is combined with Doxepin.
Codeine Anhydrous
The risk or severity of adverse effects can be increased when Codeine is combined with Doxepin.
CODEINE POLISTIREX
The risk or severity of adverse effects can be increased when Codeine is combined with Doxepin.
Colchicine
The serum concentration of Colchicine can be increased when it is combined with Doxepin.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Doxepin.
Crisaborole
The metabolism of Doxepin can be decreased when combined with Crisaborole.
Crizotinib
The metabolism of Doxepin can be decreased when combined with Crizotinib.
Cyamemazine
The risk or severity of adverse effects can be increased when Doxepin is combined with Cyamemazine.
Cyclizine
The risk or severity of adverse effects can be increased when Doxepin is combined with Cyclizine.
Cyclobenzaprine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Doxepin.
Cyclosporine
The metabolism of Doxepin can be decreased when combined with Cyclosporine.
Cyproheptadine
The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Doxepin.
Cyproterone Acetate
The serum concentration of Doxepin can be decreased when it is combined with Cyproterone acetate.
Cysteamine
The therapeutic efficacy of Cysteamine can be decreased when used in combination with Doxepin.
Dabigatran Etexilate
The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Doxepin.
Dabrafenib
The serum concentration of Doxepin can be decreased when it is combined with Dabrafenib.
Dantrolene
The risk or severity of adverse effects can be increased when Doxepin is combined with Dantrolene.
Dapiprazole
The risk or severity of adverse effects can be increased when Doxepin is combined with Dapiprazole.
Darifenacin
The metabolism of Doxepin can be decreased when combined with Darifenacin.
Darunavir
The serum concentration of Doxepin can be increased when it is combined with Darunavir.
Dasatinib
Doxepin can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dasatinib Anhydrous
Doxepin can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Deferasirox
The serum concentration of Doxepin can be decreased when it is combined with Deferasirox.
Delavirdine
Doxepin can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Doxepin.
Desipramine
The risk or severity of adverse effects can be increased when Doxepin is combined with Desipramine.
Desloratadine
The risk or severity of adverse effects can be increased when Desloratadine is combined with Doxepin.
Desmopressin
The risk or severity of adverse effects can be increased when Doxepin is combined with Desmopressin.
Desvenlafaxine
The risk or severity of adverse effects can be increased when Doxepin is combined with Desvenlafaxine.
Dexbrompheniramine
The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Doxepin.
Dexmedetomidine
Doxepin may decrease the antihypertensive activities of Dexmedetomidine.
Dexmethylphenidate
The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Doxepin.
Dextroamphetamine
Dextroamphetamine may decrease the sedative activities of Doxepin.
Dextromethorphan
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Doxepin.
Dextromoramide
The risk or severity of adverse effects can be increased when Doxepin is combined with Dextromoramide.
Dezocine
The risk or severity of adverse effects can be increased when Doxepin is combined with Dezocine.
Diazepam
The risk or severity of adverse effects can be increased when Diazepam is combined with Doxepin.
Dibucaine
The risk or severity of adverse effects can be increased when Doxepin is combined with Cinchocaine.
Dicumarol
Doxepin may increase the anticoagulant activities of Dicoumarol.
Diethylpropion
Diethylpropion may decrease the sedative activities of Doxepin.
Difenoxin
The risk or severity of adverse effects can be increased when Doxepin is combined with Difenoxin.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Doxepin.
Dihydroergotamine
Doxepin may decrease the antihypertensive activities of Dihydroergotamine.
Diltiazem
The metabolism of Doxepin can be decreased when combined with Diltiazem.
Dimenhydrinate
The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Doxepin.
Diphenhydramine
The metabolism of Doxepin can be decreased when combined with Diphenhydramine.
Diphenoxylate
The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Doxepin.
Dipivefrin
Doxepin may decrease the antihypertensive activities of Dipivefrin.
Disopyramide
Doxepin may increase the QTc-prolonging activities of Disopyramide.
Dobutamine
The risk or severity of adverse effects can be increased when Doxepin is combined with Dobutamine.
Dofetilide
Doxepin may increase the QTc-prolonging activities of Dofetilide.
Dolasetron
Doxepin may increase the QTc-prolonging activities of Dolasetron.
Domperidone
Doxepin may increase the QTc-prolonging activities of Domperidone.
Dothiepin
The metabolism of Doxepin can be decreased when combined with Dosulepin.
Doxorubicin
The serum concentration of Doxorubicin can be increased when it is combined with Doxepin.
Doxorubicin Hydrochloride
The serum concentration of Doxorubicin can be increased when it is combined with Doxepin.
Doxycycline
The metabolism of Doxepin can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Doxepin can be decreased when combined with Doxycycline.
Doxylamine
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Dronedarone
Doxepin may increase the QTc-prolonging activities of Dronedarone.
Droperidol
Droperidol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Droxidopa
Doxepin may decrease the antihypertensive activities of Droxidopa.
Duloxetine
Duloxetine may increase the serotonergic activities of Doxepin.
Dyclonine
The risk or severity of adverse effects can be increased when Doxepin is combined with Dyclonine.
Edoxaban
The serum concentration of Edoxaban can be increased when it is combined with Doxepin.
Efavirenz
The metabolism of Doxepin can be decreased when combined with Efavirenz.
Eletriptan
The risk or severity of adverse effects can be increased when Eletriptan is combined with Doxepin.
Eliglustat
Doxepin may increase the QTc-prolonging activities of Eliglustat.
Enalapril
The serum concentration of Doxepin can be increased when it is combined with Enalapril.
Enalaprilat
The serum concentration of Doxepin can be increased when it is combined with Enalaprilat.
Enalaprilat Anhydrous
The serum concentration of Doxepin can be increased when it is combined with Enalaprilat.
Enflurane
The risk or severity of adverse effects can be increased when Doxepin is combined with Enflurane.
Entacapone
The risk or severity of adverse effects can be increased when Entacapone is combined with Doxepin.
Enzalutamide
The serum concentration of Doxepin can be decreased when it is combined with Enzalutamide.
Epigallocatechin Gallate
The serum concentration of Doxepin can be increased when it is combined with Epigallocatechin Gallate.
Epinephrine
Doxepin may decrease the antihypertensive activities of Epinephrine.
ergoloid mesylates, USP
The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Doxepin.
Ergonovine
The risk or severity of adverse effects can be increased when Doxepin is combined with Ergonovine.
Ergotamine
Doxepin may decrease the antihypertensive activities of Ergotamine.
Erlotinib
The serum concentration of Erlotinib can be decreased when it is combined with Doxepin.
Erythromycin
The metabolism of Doxepin can be decreased when combined with Erythromycin.
Escitalopram
The risk or severity of adverse effects can be increased when Doxepin is combined with Escitalopram.
Eslicarbazepine Acetate
The metabolism of Doxepin can be decreased when combined with Eslicarbazepine acetate.
Esomeprazole
The metabolism of Doxepin can be decreased when combined with Esomeprazole.
Estazolam
The risk or severity of adverse effects can be increased when Estazolam is combined with Doxepin.
Eszopiclone
The risk or severity of adverse effects can be increased when Eszopiclone is combined with Doxepin.
Ethanol
Doxepin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Ethchlorvynol
The risk or severity of adverse effects can be increased when Doxepin is combined with Ethchlorvynol.
Ethosuximide
The risk or severity of adverse effects can be increased when Ethosuximide is combined with Doxepin.
Ethotoin
The risk or severity of adverse effects can be increased when Ethotoin is combined with Doxepin.
Ethyl Chloride
The risk or severity of adverse effects can be increased when Doxepin is combined with Ethyl chloride.
Ethyl Loflazepate
The risk or severity of adverse effects can be increased when Doxepin is combined with Ethyl loflazepate.
Ethylmorphine
The risk or severity of adverse effects can be increased when Doxepin is combined with Ethylmorphine.
Etidocaine
The risk or severity of adverse effects can be increased when Doxepin is combined with Etidocaine.
Etifoxine
The risk or severity of adverse effects can be increased when Doxepin is combined with Etifoxine.
Etomidate
Doxepin may decrease the antihypertensive activities of Etomidate.
Etravirine
The metabolism of Doxepin can be decreased when combined with Etravirine.
Everolimus
The serum concentration of Everolimus can be increased when it is combined with Doxepin.
Ezogabine
The risk or severity of adverse effects can be increased when Doxepin is combined with Ezogabine.
Felbamate
The risk or severity of adverse effects can be increased when Felbamate is combined with Doxepin.
Fenoterol
The risk or severity of adverse effects can be increased when Doxepin is combined with Fenoterol.
Fentanyl
The risk or severity of adverse effects can be increased when Fentanyl is combined with Doxepin.
Ferric Carboxymaltose
Doxepin can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric Pyrophosphate
Doxepin can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fesoterodine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Doxepin.
Fexofenadine
The risk or severity of adverse effects can be increased when Fexofenadine is combined with Doxepin.
Fibrinolysis Inhibitor
The serum concentration of Doxepin can be increased when it is combined with Aprotinin.
Flecainide
Doxepin may increase the QTc-prolonging activities of Flecainide.
Flibanserin
The risk or severity of adverse effects can be increased when Doxepin is combined with Flibanserin.
Floxuridine
The metabolism of Doxepin can be decreased when combined with Floxuridine.
Fluconazole
The metabolism of Doxepin can be decreased when combined with Fluconazole.
Fluindione
Doxepin may increase the anticoagulant activities of Fluindione.
Flunarizine
The risk or severity of adverse effects can be increased when Doxepin is combined with Flunarizine.
Flunitrazepam
The risk or severity of adverse effects can be increased when Doxepin is combined with Flunitrazepam.
Fluorouracil
The metabolism of Doxepin can be decreased when combined with Fluorouracil.
Fluoxetine
The risk or severity of adverse effects can be increased when Fluoxetine is combined with Doxepin.
Flupenthixol
Doxepin may increase the QTc-prolonging activities of Flupentixol.
Fluphenazine
The risk or severity of adverse effects can be increased when Fluphenazine is combined with Doxepin.
Flurazepam
The risk or severity of adverse effects can be increased when Flurazepam is combined with Doxepin.
Fluspirilene
The risk or severity of adverse effects can be increased when Doxepin is combined with Fluspirilene.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Doxepin.
Fluvastatin
The metabolism of Doxepin can be decreased when combined with Fluvastatin.
Fluvoxamine
The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Doxepin.
Formoterol
The risk or severity of adverse effects can be increased when Doxepin is combined with Formoterol.
Fosamprenavir
The serum concentration of Fosamprenavir can be decreased when it is combined with Doxepin.
Fosaprepitant
The serum concentration of Doxepin can be increased when it is combined with Fosaprepitant.
Fosinopril
The serum concentration of Doxepin can be increased when it is combined with Fosinopril.
Fosphenytoin
The metabolism of Doxepin can be increased when combined with Fosphenytoin.
Fospropofol
The risk or severity of adverse effects can be increased when Doxepin is combined with Fospropofol.
Frovatriptan
The risk or severity of adverse effects can be increased when Frovatriptan is combined with Doxepin.
Furazolidone
Furazolidone may increase the serotonergic activities of Doxepin.
Fusidate
The serum concentration of Doxepin can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Doxepin can be increased when it is combined with Fusidic Acid.
Gabapentin
The risk or severity of adverse effects can be increased when Gabapentin is combined with Doxepin.
Gabapentin Enacarbil
The risk or severity of adverse effects can be increased when Doxepin is combined with Gabapentin Enacarbil.
Gadobenate
Doxepin may increase the QTc-prolonging activities of Gadobenic acid.
Gefitinib
The serum concentration of Gefitinib can be decreased when it is combined with Doxepin.
Gemfibrozil
The metabolism of Doxepin can be decreased when combined with Gemfibrozil.
Gemifloxacin
Doxepin may increase the QTc-prolonging activities of Gemifloxacin.
Gemifloxacin Mesylate
Doxepin may increase the QTc-prolonging activities of Gemifloxacin.
Glutethimide
The risk or severity of adverse effects can be increased when Doxepin is combined with Glutethimide.
Goserelin
Doxepin may increase the QTc-prolonging activities of Goserelin.
Granisetron
Doxepin may increase the QTc-prolonging activities of Granisetron.
Guanabenz
Doxepin may decrease the antihypertensive activities of Guanabenz.
Guanfacine
Doxepin may decrease the antihypertensive activities of Guanfacine.
Halazepam
The risk or severity of adverse effects can be increased when Doxepin is combined with Halazepam.
Haloperidol
The metabolism of Doxepin can be decreased when combined with Haloperidol.
Halothane
The risk or severity of adverse effects can be increased when Doxepin is combined with Halothane.
Heroin
The risk or severity of adverse effects can be increased when Doxepin is combined with Heroin.
Hexobarbital
The metabolism of Doxepin can be increased when combined with Hexobarbital.
Hyaluronidase
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Doxepin.
Hyaluronidase, Ovine
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Doxepin.
Hydrocodone
Doxepin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HYDROCODONE POLISTIREX
Doxepin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydromorphone
The risk or severity of adverse effects can be increased when Hydromorphone is combined with Doxepin.
Hydroxyzine
Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Hypoxis hemerocallidea root extract
The metabolism of Doxepin can be increased when combined with St. John's Wort.
Ibutilide
Doxepin may increase the QTc-prolonging activities of Ibutilide.
Idelalisib
The metabolism of Doxepin can be decreased when combined with Idelalisib.
Iloperidone
Doxepin may increase the QTc-prolonging activities of Iloperidone.
Imatinib
The metabolism of Doxepin can be decreased when combined with Imatinib.
Imidapril
The serum concentration of Doxepin can be increased when it is combined with Imidapril.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Doxepin.
Indacaterol
The risk or severity of adverse effects can be increased when Doxepin is combined with Indacaterol.
Indinavir
The serum concentration of Indinavir can be decreased when it is combined with Doxepin.
INDINAVIR ANHYDROUS
The serum concentration of Indinavir can be decreased when it is combined with Doxepin.
Iproniazid
Iproniazid may increase the serotonergic activities of Doxepin.
Irbesartan
The metabolism of Doxepin can be decreased when combined with Irbesartan.
Iron
Doxepin can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron Carbonyl
Doxepin can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron Sucrose
Doxepin can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron-Dextran Complex
Doxepin can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
Isavuconazole
The serum concentration of Doxepin can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Doxepin can be decreased when combined with Isavuconazonium.
Isocarboxazid
The therapeutic efficacy of Doxepin can be increased when used in combination with Isocarboxazid.
Isoetharine
The risk or severity of adverse effects can be increased when Doxepin is combined with Isoetarine.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Doxepin.
Isoflurophate
The serum concentration of Doxepin can be increased when it is combined with Isoflurophate.
Isoniazid
The metabolism of Doxepin can be decreased when combined with Isoniazid.
Isoproterenol
The risk or severity of adverse effects can be increased when Doxepin is combined with Isoprenaline.
Isradipine
The metabolism of Doxepin can be decreased when combined with Isradipine.
Itraconazole
The serum concentration of Itraconazole can be decreased when it is combined with Doxepin.
Ivacaftor
The serum concentration of Doxepin can be increased when it is combined with Ivacaftor.
Ixazomib
The serum concentration of Doxepin can be increased when it is combined with Ixazomib.
Ketamine
The risk or severity of adverse effects can be increased when Ketamine is combined with Doxepin.
Ketazolam
The risk or severity of adverse effects can be increased when Doxepin is combined with Ketazolam.
Ketoconazole
The serum concentration of Ketoconazole can be decreased when it is combined with Doxepin.
Lamotrigine
The risk or severity of adverse effects can be increased when Lamotrigine is combined with Doxepin.
Ledipasvir
The serum concentration of Ledipasvir can be decreased when it is combined with Doxepin.
Leflunomide
The metabolism of Doxepin can be decreased when combined with Leflunomide.
Lenvatinib
Doxepin may increase the QTc-prolonging activities of Lenvatinib.
Lenvatinib Mesylate
Doxepin may increase the QTc-prolonging activities of Lenvatinib.
Lepirudin
The serum concentration of Doxepin can be increased when it is combined with Lepirudin.
Leuprolide
Doxepin may increase the QTc-prolonging activities of Leuprolide.
Levalbuterol
The risk or severity of adverse effects can be increased when Doxepin is combined with Levosalbutamol.
Levetiracetam
The risk or severity of adverse effects can be increased when Doxepin is combined with Levetiracetam.
Levobupivacaine
The risk or severity of adverse effects can be increased when Doxepin is combined with Levobupivacaine.
Levocabastine
The risk or severity of adverse effects can be increased when Doxepin is combined with Levocabastine.
Levocetirizine
The risk or severity of adverse effects can be increased when Doxepin is combined with Levocetirizine.
Levodopa
The risk or severity of adverse effects can be increased when Doxepin is combined with Levodopa.
Levofloxacin
Doxepin may increase the QTc-prolonging activities of Levofloxacin.
Levofloxacin Anhydrous
Doxepin may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl
The risk or severity of adverse effects can be increased when Doxepin is combined with Levomethadyl Acetate.
Levomilnacipran
The risk or severity of adverse effects can be increased when Doxepin is combined with Levomilnacipran.
Levonordefrin
Doxepin may decrease the antihypertensive activities of Levonordefrin.
Levorphanol
The risk or severity of adverse effects can be increased when Levorphanol is combined with Doxepin.
Levothyroxine
Levothyroxine may increase the arrhythmogenic activities of Doxepin.
Lidocaine
The metabolism of Doxepin can be decreased when combined with Lidocaine.
Linagliptin
The serum concentration of Doxepin can be increased when it is combined with Linagliptin.
Linezolid
Linezolid may increase the serotonergic activities of Doxepin.
Liothyronine
Liothyronine may increase the arrhythmogenic activities of Doxepin.
Lisdexamfetamine
Lisdexamfetamine may decrease the sedative activities of Doxepin.
Lisdexamfetamine Dimesylate
Lisdexamfetamine may decrease the sedative activities of Doxepin.
Lisinopril
The serum concentration of Doxepin can be increased when it is combined with Lisinopril.
Lisinopril Anhydrous
The serum concentration of Doxepin can be increased when it is combined with Lisinopril.
Lithium
Lithium may increase the neurotoxic activities of Doxepin.
Lithium Cation
Lithium may increase the neurotoxic activities of Doxepin.
Lofexidine
Doxepin may decrease the antihypertensive activities of Lofexidine.
Lopinavir
The metabolism of Doxepin can be decreased when combined with Lopinavir.
Loratadine
The risk or severity of adverse effects can be increased when Loratadine is combined with Doxepin.
Lorazepam
The risk or severity of adverse effects can be increased when Lorazepam is combined with Doxepin.
Lorcaserin
The risk or severity of adverse effects can be increased when Doxepin is combined with Lorcaserin.
Lormetazepam
The risk or severity of adverse effects can be increased when Doxepin is combined with Lormetazepam.
Losartan
The metabolism of Doxepin can be decreased when combined with Losartan.
Lovastatin
The metabolism of Doxepin can be decreased when combined with Lovastatin.
Loxapine
The risk or severity of adverse effects can be increased when Loxapine is combined with Doxepin.
Luliconazole
The serum concentration of Doxepin can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Doxepin can be decreased when it is combined with Lumacaftor.
Lumefantrine
Doxepin may increase the QTc-prolonging activities of Lumefantrine.
Lurasidone
The risk or severity of adverse effects can be increased when Lurasidone is combined with Doxepin.
Magnesium Sulfate
The therapeutic efficacy of Doxepin can be increased when used in combination with Magnesium sulfate.
MAGNESIUM SULFATE ANHYDROUS
The therapeutic efficacy of Doxepin can be increased when used in combination with Magnesium sulfate.
Manidipine
The metabolism of Doxepin can be decreased when combined with Manidipine.
Maprotiline
The risk or severity of adverse effects can be increased when Maprotiline is combined with Doxepin.
Meclizine
The risk or severity of adverse effects can be increased when Meclizine is combined with Doxepin.
Melatonin
The risk or severity of adverse effects can be increased when Doxepin is combined with Melatonin.
Meperidine
The risk or severity of adverse effects can be increased when Pethidine is combined with Doxepin.
Mephentermine
Doxepin may increase the vasopressor activities of Mephentermine.
Mephobarbital
The metabolism of Doxepin can be increased when combined with Methylphenobarbital.
Mepivacaine
The risk or severity of adverse effects can be increased when Doxepin is combined with Mepivacaine.
Meprobamate
The risk or severity of adverse effects can be increased when Meprobamate is combined with Doxepin.
Mesalamine
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Doxepin.
Mesoridazine
The risk or severity of adverse effects can be increased when Doxepin is combined with Mesoridazine.
Metaproterenol
The risk or severity of adverse effects can be increased when Doxepin is combined with Orciprenaline.
Metaraminol
Doxepin may increase the vasopressor activities of Metaraminol.
Metaxalone
The risk or severity of adverse effects can be increased when Metaxalone is combined with Doxepin.
Methadone
The risk or severity of adverse effects can be increased when Methadone is combined with Doxepin.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Doxepin is combined with Methadyl Acetate.
Methamphetamine
Doxepin may decrease the antihypertensive activities of Methamphetamine.
Methapyrilene
The risk or severity of adverse effects can be increased when Doxepin is combined with Methapyrilene.
Methaqualone
The risk or severity of adverse effects can be increased when Doxepin is combined with Methaqualone.
Methocarbamol
The risk or severity of adverse effects can be increased when Methocarbamol is combined with Doxepin.
Methohexital
The metabolism of Doxepin can be increased when combined with Methohexital.
Methotrimeprazine
Doxepin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Methoxamine
Doxepin may increase the vasopressor activities of Methoxamine.
Methoxyflurane
The risk or severity of adverse effects can be increased when Doxepin is combined with Methoxyflurane.
Methsuximide
The risk or severity of adverse effects can be increased when Doxepin is combined with Methsuximide.
Methylene blue
Doxepin may increase the serotonergic activities of Methylene blue.
Methylphenidate
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Doxepin.
Metoclopramide
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Doxepin.
Metoprolol
The serum concentration of Metoprolol can be increased when it is combined with Doxepin.
Metylperon
The risk or severity of adverse effects can be increased when Doxepin is combined with Melperone.
Metyrosine
The risk or severity of adverse effects can be increased when Metyrosine is combined with Doxepin.
Mexiletine
The metabolism of Doxepin can be decreased when combined with Mexiletine.
Midazolam
The risk or severity of adverse effects can be increased when Midazolam is combined with Doxepin.
Midodrine
Doxepin may increase the vasopressor activities of Midodrine.
Midostaurin
The metabolism of Doxepin can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Doxepin can be increased when it is combined with Mifepristone.
Milnacipran
The risk or severity of adverse effects can be increased when Doxepin is combined with Milnacipran.
Minaprine
Minaprine may increase the serotonergic activities of Doxepin.
Minocycline
Minocycline may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Mirabegron
The metabolism of Doxepin can be decreased when combined with Mirabegron.
Mirtazapine
Doxepin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Mitotane
The serum concentration of Doxepin can be decreased when it is combined with Mitotane.
Moclobemide
Moclobemide may increase the serotonergic activities of Doxepin.
Modafinil
The metabolism of Doxepin can be decreased when combined with Modafinil.
Moexipril
The serum concentration of Doxepin can be increased when it is combined with Moexipril.
Molindone
The risk or severity of adverse effects can be increased when Doxepin is combined with Molindone.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Doxepin.
Moxifloxacin
Doxepin may increase the QTc-prolonging activities of Moxifloxacin.
Moxonidine
The therapeutic efficacy of Moxonidine can be decreased when used in combination with Doxepin.
Nabilone
Nabilone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Nalbuphine
The risk or severity of adverse effects can be increased when Nalbuphine is combined with Doxepin.
Naloxegol
The serum concentration of Naloxegol can be increased when it is combined with Doxepin.
Naphazoline
Doxepin may decrease the antihypertensive activities of Naphazoline.
Naratriptan
The risk or severity of adverse effects can be increased when Naratriptan is combined with Doxepin.
Nefazodone
The metabolism of Doxepin can be decreased when combined with Nefazodone.
Nelfinavir
The serum concentration of Nelfinavir can be decreased when it is combined with Doxepin.
Netupitant
The serum concentration of Doxepin can be increased when it is combined with Netupitant.
Nevirapine
The metabolism of Doxepin can be increased when combined with Nevirapine.
Nialamide
Nialamide may increase the serotonergic activities of Doxepin.
Nicardipine
The metabolism of Doxepin can be decreased when combined with Nicardipine.
Nicorandil
Doxepin may increase the hypotensive activities of Nicorandil.
Nilotinib
The serum concentration of Nilotinib can be decreased when it is combined with Doxepin.
Nitrazepam
The risk or severity of adverse effects can be increased when Nitrazepam is combined with Doxepin.
Nitrous Oxide
The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Doxepin.
Norepinephrine
Doxepin may decrease the antihypertensive activities of Norepinephrine.
Norflurane
The risk or severity of adverse effects can be increased when Doxepin is combined with Norflurane.
Normethadone
The risk or severity of adverse effects can be increased when Doxepin is combined with Normethadone.
Nortriptyline
The risk or severity of adverse effects can be increased when Nortriptyline is combined with Doxepin.
O-PHENANTHROLINE
The serum concentration of Doxepin can be increased when it is combined with 1,10-Phenanthroline.
Ofloxacin
Doxepin may increase the QTc-prolonging activities of Ofloxacin.
Olanzapine
The risk or severity of adverse effects can be increased when Olanzapine is combined with Doxepin.
Olaparib
The metabolism of Doxepin can be decreased when combined with Olaparib.
Olodaterol
The risk or severity of adverse effects can be increased when Doxepin is combined with Olodaterol.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Doxepin.
Omeprazole
The metabolism of Doxepin can be decreased when combined with Omeprazole.
Ondansetron
Doxepin may increase the QTc-prolonging activities of Ondansetron.
Opium
The risk or severity of adverse effects can be increased when Doxepin is combined with Opium.
Orphenadrine
Doxepin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Osimertinib
The serum concentration of Doxepin can be increased when it is combined with Osimertinib.
Oxazepam
The risk or severity of adverse effects can be increased when Oxazepam is combined with Doxepin.
Oxprenolol
The risk or severity of adverse effects can be increased when Doxepin is combined with Oxprenolol.
Oxycodone
The risk or severity of adverse effects can be increased when Oxycodone is combined with Doxepin.
Oxymetazoline
Doxepin may decrease the antihypertensive activities of Oxymetazoline.
Oxymorphone
The risk or severity of adverse effects can be increased when Oxymorphone is combined with Doxepin.
p-Hydroxyamphetamine
Hydroxyamphetamine may decrease the sedative activities of Doxepin.
Palbociclib
The serum concentration of Doxepin can be increased when it is combined with Palbociclib.
Paliperidone
Doxepin may decrease the antihypertensive activities of Paliperidone.
Palonosetron
Palonosetron may increase the serotonergic activities of Doxepin.
Panobinostat
The serum concentration of Doxepin can be increased when it is combined with Panobinostat.
Pantoprazole
The metabolism of Doxepin can be decreased when combined with Pantoprazole.
Paraldehyde
Doxepin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Paregoric
The risk or severity of adverse effects can be increased when Morphine is combined with Doxepin.
Pargyline
Pargyline may increase the serotonergic activities of Doxepin.
Paroxetine
The risk or severity of adverse effects can be increased when Paroxetine is combined with Doxepin.
Pazopanib
The serum concentration of Pazopanib can be increased when it is combined with Doxepin.
Peginterferon Alfa-2b
The serum concentration of Doxepin can be decreased when it is combined with Peginterferon alfa-2b.
Pentamidine
Doxepin may increase the QTc-prolonging activities of Pentamidine.
Pentazocine
The risk or severity of adverse effects can be increased when Pentazocine is combined with Doxepin.
Pentobarbital
The metabolism of Doxepin can be increased when combined with Pentobarbital.
Perampanel
Perampanel may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Perazine
The risk or severity of adverse effects can be increased when Doxepin is combined with Perazine.
Perflutren
Doxepin may increase the QTc-prolonging activities of Perflutren.
Pergolide
Doxepin may decrease the antihypertensive activities of Pergolide.
Periciazine
The risk or severity of adverse effects can be increased when Doxepin is combined with Propericiazine.
Perindopril
The serum concentration of Doxepin can be increased when it is combined with Perindopril.
Perphenazine
The risk or severity of adverse effects can be increased when Perphenazine is combined with Doxepin.
Phenelzine
Phenelzine may increase the serotonergic activities of Doxepin.
Phenindione
Doxepin may increase the anticoagulant activities of Phenindione.
Phenobarbital
The metabolism of Doxepin can be increased when combined with Phenobarbital.
Phenoxyethanol
The risk or severity of adverse effects can be increased when Doxepin is combined with Phenoxyethanol.
Phenprocoumon
Doxepin may increase the anticoagulant activities of Phenprocoumon.
Phentermine
Phentermine may decrease the sedative activities of Doxepin.
PHENTERMINE RESIN
Phentermine may decrease the sedative activities of Doxepin.
Phenylephrine
Doxepin may increase the vasopressor activities of Phenylephrine.
Phenylpropanolamine
The risk or severity of adverse effects can be increased when Doxepin is combined with Phenylpropanolamine.
Phenytoin
The metabolism of Doxepin can be increased when combined with Phenytoin.
Pimozide
Doxepin may increase the QTc-prolonging activities of Pimozide.
Pipamperone
The risk or severity of adverse effects can be increased when Doxepin is combined with Pipamperone.
Pipothiazine
The risk or severity of adverse effects can be increased when Doxepin is combined with Pipotiazine.
Pirbuterol
The risk or severity of adverse effects can be increased when Doxepin is combined with Pirbuterol.
Pirinitramide
The risk or severity of adverse effects can be increased when Doxepin is combined with Piritramide.
Pizotyline
The risk or severity of adverse effects can be increased when Doxepin is combined with Pizotifen.
Pomalidomide
The risk or severity of adverse effects can be increased when Doxepin is combined with Pomalidomide.
Posaconazole
The serum concentration of Posaconazole can be decreased when it is combined with Doxepin.
Pramipexole
Doxepin may increase the sedative activities of Pramipexole.
Pramoxine
The risk or severity of adverse effects can be increased when Doxepin is combined with Pramocaine.
Prazepam
The risk or severity of adverse effects can be increased when Doxepin is combined with Prazepam.
Pregabalin
The therapeutic efficacy of Doxepin can be increased when used in combination with Pregabalin.
Prilocaine
The risk or severity of adverse effects can be increased when Doxepin is combined with Prilocaine.
Primaquine
Doxepin may increase the QTc-prolonging activities of Primaquine.
Primidone
The metabolism of Doxepin can be increased when combined with Primidone.
Procainamide
Doxepin may increase the QTc-prolonging activities of Procainamide.
Procaine
The risk or severity of adverse effects can be increased when Doxepin is combined with Procaine.
Procarbazine
Procarbazine may increase the serotonergic activities of Doxepin.
Procaterol
The risk or severity of adverse effects can be increased when Doxepin is combined with Procaterol.
Prochlorperazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Doxepin.
Promazine
The metabolism of Doxepin can be decreased when combined with Promazine.
Promethazine
The risk or severity of adverse effects can be increased when Promethazine is combined with Doxepin.
Propafenone
Doxepin may increase the QTc-prolonging activities of Propafenone.
Proparacaine
The risk or severity of adverse effects can be increased when Doxepin is combined with Proparacaine.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Doxepin.
Propoxyphene
The risk or severity of adverse effects can be increased when Doxepin is combined with Dextropropoxyphene.
Prothipendyl
The risk or severity of adverse effects can be increased when Doxepin is combined with Prothipendyl.
Protriptyline
The risk or severity of adverse effects can be increased when Protriptyline is combined with Doxepin.
Pseudoephedrine
Doxepin may decrease the antihypertensive activities of Pseudoephedrine.
Pyrimethamine
The metabolism of Doxepin can be decreased when combined with Pyrimethamine.
Quazepam
The risk or severity of adverse effects can be increased when Quazepam is combined with Doxepin.
Quetiapine
Doxepin may increase the QTc-prolonging activities of Quetiapine.
Quetiapine fumarate
Doxepin may increase the QTc-prolonging activities of Quetiapine.
Quinapril
The serum concentration of Doxepin can be increased when it is combined with Quinapril.
Quinidine
Doxepin may increase the QTc-prolonging activities of Quinidine.
Quinine
Doxepin may increase the QTc-prolonging activities of Quinine.
Racecadotril
The serum concentration of Doxepin can be increased when it is combined with Racecadotril.
Ramelteon
The risk or severity of adverse effects can be increased when Ramelteon is combined with Doxepin.
Ramipril
The serum concentration of Doxepin can be increased when it is combined with Ramipril.
Ranolazine
The serum concentration of Ranolazine can be increased when it is combined with Doxepin.
Rasagiline
Rasagiline may increase the serotonergic activities of Doxepin.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Doxepin.
Remoxipride
The risk or severity of adverse effects can be increased when Doxepin is combined with Remoxipride.
Reserpine
The risk or severity of adverse effects can be increased when Reserpine is combined with Doxepin.
Rifabutin
The metabolism of Doxepin can be increased when combined with Rifabutin.
Rifampin
The metabolism of Doxepin can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Doxepin can be increased when combined with Rifapentine.
Rifaximin
The serum concentration of Rifaximin can be increased when it is combined with Doxepin.
Risedronate
Doxepin can cause an increase in the absorption of Risedronate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Risedronic Acid
Doxepin can cause an increase in the absorption of Risedronate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Risperidone
Doxepin may decrease the antihypertensive activities of Risperidone.
Ritodrine
The risk or severity of adverse effects can be increased when Doxepin is combined with Ritodrine.
Ritonavir
The metabolism of Doxepin can be decreased when combined with Ritonavir.
Rivaroxaban
The serum concentration of Doxepin can be increased when it is combined with Rivaroxaban.
Rizatriptan
The risk or severity of adverse effects can be increased when Rizatriptan is combined with Doxepin.
Rolapitant
The metabolism of Doxepin can be decreased when combined with Rolapitant.
Ropinirole
Doxepin may increase the sedative activities of Ropinirole.
Ropivacaine
The risk or severity of adverse effects can be increased when Doxepin is combined with Ropivacaine.
Rotigotine
Doxepin may increase the sedative activities of Rotigotine.
Rucaparib
The metabolism of Doxepin can be decreased when combined with Rucaparib.
Rufinamide
The risk or severity of adverse effects can be increased when Rufinamide is combined with Doxepin.
Salmeterol
The risk or severity of adverse effects can be increased when Doxepin is combined with Salmeterol.
Saquinavir
The serum concentration of Saquinavir can be increased when it is combined with Doxepin.
Saquinavir Mesylate
The serum concentration of Saquinavir can be increased when it is combined with Doxepin.
Sarilumab
The therapeutic efficacy of Doxepin can be decreased when used in combination with Sarilumab.
Saxagliptin
The serum concentration of Doxepin can be increased when it is combined with Saxagliptin.
Saxagliptin Anhydrous
The serum concentration of Doxepin can be increased when it is combined with Saxagliptin.
Scopolamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Doxepin.
Scopolamine Hydrobromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Doxepin.
Secobarbital
The metabolism of Doxepin can be increased when combined with Secobarbital.
Selegiline
Selegiline may increase the serotonergic activities of Doxepin.
Sertindole
The risk or severity of adverse effects can be increased when Doxepin is combined with Sertindole.
Sertraline
The risk or severity of adverse effects can be increased when Sertraline is combined with Doxepin.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Doxepin.
Sildenafil
The metabolism of Doxepin can be decreased when combined with Sildenafil.
Silodosin
The serum concentration of Silodosin can be increased when it is combined with Doxepin.
Siltuximab
The serum concentration of Doxepin can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Doxepin can be increased when it is combined with Simeprevir.
Sitagliptin
The serum concentration of Doxepin can be increased when it is combined with Sitagliptin.
Sitagliptin Phosphate
The serum concentration of Doxepin can be increased when it is combined with Sitagliptin.
Sodium Oxybate
Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Sodium Phosphate
The risk or severity of adverse effects can be increased when Doxepin is combined with Sodium phosphate.
Sodium Phosphate, Monobasic
The risk or severity of adverse effects can be increased when Doxepin is combined with Sodium phosphate.
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
The risk or severity of adverse effects can be increased when Doxepin is combined with Sodium phosphate.
Sorafenib
The metabolism of Doxepin can be decreased when combined with Sorafenib.
Sotalol
Doxepin may increase the QTc-prolonging activities of Sotalol.
Spirapril
The serum concentration of Doxepin can be increased when it is combined with Spirapril.
ST. JOHN'S WORT EXTRACT
The metabolism of Doxepin can be increased when combined with St. John's Wort.
Sucroferric Oxyhydroxide
Doxepin can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Doxepin.
Sulfadiazine
The metabolism of Doxepin can be decreased when combined with Sulfadiazine.
Sulfamethoxazole
The metabolism of Doxepin can be decreased when combined with Sulfamethoxazole.
Sulfisoxazole
The metabolism of Doxepin can be decreased when combined with Sulfisoxazole.
Sulpiride
The risk or severity of adverse effects can be increased when Doxepin is combined with Sulpiride.
Sumatriptan
The risk or severity of adverse effects can be increased when Sumatriptan is combined with Doxepin.
Sumatriptan Succinate
The risk or severity of adverse effects can be increased when Sumatriptan is combined with Doxepin.
Suvorexant
Doxepin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Tasimelteon
The risk or severity of adverse effects can be increased when Doxepin is combined with Tasimelteon.
Tedizolid
Tedizolid Phosphate may increase the serotonergic activities of Doxepin.
Tedizolid Phosphate
Tedizolid Phosphate may increase the serotonergic activities of Doxepin.
Telaprevir
The metabolism of Doxepin can be decreased when combined with Telaprevir.
Telavancin
Doxepin may increase the QTc-prolonging activities of Telavancin.
Telithromycin
The metabolism of Doxepin can be decreased when combined with Telithromycin.
Temazepam
The risk or severity of adverse effects can be increased when Temazepam is combined with Doxepin.
Tenofovir Disoproxil
The metabolism of Doxepin can be decreased when combined with Tenofovir disoproxil.
Terbinafine
The metabolism of Doxepin can be decreased when combined with Terbinafine.
Terbutaline
The risk or severity of adverse effects can be increased when Doxepin is combined with Terbutaline.
Terbutaline Sulfate
The risk or severity of adverse effects can be increased when Doxepin is combined with Terbutaline.
Teriflunomide
The serum concentration of Doxepin can be decreased when it is combined with Teriflunomide.
Tetrabenazine
Doxepin may increase the QTc-prolonging activities of Tetrabenazine.
Tetracaine
The risk or severity of adverse effects can be increased when Doxepin is combined with Tetracaine.
Tetracaine hydrochloride
The risk or severity of adverse effects can be increased when Doxepin is combined with Tetracaine.
Tetrahydrocannabinol
Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Thalidomide
Doxepin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Theophylline
The metabolism of Doxepin can be decreased when combined with Theophylline.
Theophylline anhydrous
The metabolism of Doxepin can be decreased when combined with Theophylline.
Thiamylal
The metabolism of Doxepin can be increased when combined with Thiamylal.
Thiopental
The metabolism of Doxepin can be increased when combined with Thiopental.
Thiopental Sodium
The metabolism of Doxepin can be increased when combined with Thiopental.
Thioproperazine
The risk or severity of adverse effects can be increased when Doxepin is combined with Thioproperazine.
Thioridazine
The serum concentration of Thioridazine can be increased when it is combined with Doxepin.
Thiothixene
The risk or severity of adverse effects can be increased when Thiothixene is combined with Doxepin.
Thyroid, Porcine
Thyroid, porcine may increase the arrhythmogenic activities of Doxepin.
Tiagabine
The risk or severity of adverse effects can be increased when Tiagabine is combined with Doxepin.
Tiapride
The risk or severity of adverse effects can be increased when Doxepin is combined with Tiapride.
Ticagrelor
The metabolism of Doxepin can be decreased when combined with Ticagrelor.
Ticlopidine
The metabolism of Doxepin can be decreased when combined with Ticlopidine.
Tipranavir
The metabolism of Doxepin can be decreased when combined with Tipranavir.
Tizanidine
Doxepin may decrease the antihypertensive activities of Tizanidine.
Tocilizumab
The serum concentration of Doxepin can be decreased when it is combined with Tocilizumab.
Tolbutamide
The metabolism of Doxepin can be decreased when combined with Tolbutamide.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Doxepin.
Toloxatone
Toloxatone may increase the serotonergic activities of Doxepin.
Topiramate
The metabolism of Doxepin can be decreased when combined with Topiramate.
Topotecan
The serum concentration of Topotecan can be increased when it is combined with Doxepin.
Toremifene
Doxepin may increase the QTc-prolonging activities of Toremifene.
Tramadol
Doxepin may increase the neuroexcitatory activities of Tramadol.
Trandolapril
The serum concentration of Doxepin can be increased when it is combined with Trandolapril.
Tranylcypromine
Tranylcypromine may increase the serotonergic activities of Doxepin.
Trazodone
The risk or severity of adverse effects can be increased when Trazodone is combined with Doxepin.
Triazolam
The risk or severity of adverse effects can be increased when Triazolam is combined with Doxepin.
Triazulenone
The risk or severity of adverse effects can be increased when Doxepin is combined with Loprazolam.
Trifluoperazine
The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Doxepin.
Triflupromazine
The risk or severity of adverse effects can be increased when Doxepin is combined with Triflupromazine.
Trimethoprim
The metabolism of Doxepin can be decreased when combined with Trimethoprim.
Trimipramine
The risk or severity of adverse effects can be increased when Trimipramine is combined with Doxepin.
Triprolidine
The risk or severity of adverse effects can be increased when Triprolidine is combined with Doxepin.
Tropisetron
Tropisetron may increase the serotonergic activities of Doxepin.
Tryptophan
L-Tryptophan may increase the serotonergic activities of Doxepin.
Urethane
The risk or severity of adverse effects can be increased when Doxepin is combined with Ethyl carbamate.
Valproate
The serum concentration of Doxepin can be increased when it is combined with Valproic Acid.
Valproic Acid
The serum concentration of Doxepin can be increased when it is combined with Valproic Acid.
Valsartan
The metabolism of Doxepin can be decreased when combined with Valsartan.
Vandetanib
Doxepin may increase the QTc-prolonging activities of Vandetanib.
Varenicline
The serum concentration of Varenicline can be increased when it is combined with Doxepin.
Vemurafenib
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Doxepin.
Venlafaxine
The risk or severity of adverse effects can be increased when Venlafaxine is combined with Doxepin.
Verapamil
The metabolism of Doxepin can be decreased when combined with Verapamil.
Vigabatrin
The risk or severity of adverse effects can be increased when Vigabatrin is combined with Doxepin.
Vilanterol
The risk or severity of adverse effects can be increased when Doxepin is combined with Vilanterol.
Vilazodone
The risk or severity of adverse effects can be increased when Vilazodone is combined with Doxepin.
Vildagliptin
The serum concentration of Doxepin can be increased when it is combined with Vildagliptin.
Vincristine
The excretion of Vincristine can be decreased when combined with Doxepin.
Voriconazole
The metabolism of Doxepin can be decreased when combined with Voriconazole.
Vortioxetine
The risk or severity of adverse effects can be increased when Vortioxetine is combined with Doxepin.
Warfarin
Doxepin may increase the anticoagulant activities of Warfarin.
Xylometazoline
Doxepin may decrease the antihypertensive activities of Xylometazoline.
Yohimbine
The serum concentration of Yohimbine can be increased when it is combined with Doxepin.
Zafirlukast
The metabolism of Doxepin can be decreased when combined with Zafirlukast.
Zaleplon
The risk or severity of adverse effects can be increased when Zaleplon is combined with Doxepin.
Ziconotide
The risk or severity of adverse effects can be increased when Doxepin is combined with Ziconotide.
Ziprasidone
Doxepin may increase the QTc-prolonging activities of Ziprasidone.
Zofenopril
The serum concentration of Doxepin can be increased when it is combined with Zofenopril.
Zolmitriptan
The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Doxepin.
Zolpidem
Doxepin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Zonisamide
The risk or severity of adverse effects can be increased when Zonisamide is combined with Doxepin.
Zopiclone
The risk or severity of adverse effects can be increased when Zopiclone is combined with Doxepin.
Zotepine
The risk or severity of adverse effects can be increased when Doxepin is combined with Zotepine.
Zuclopenthixol
Doxepin may increase the QTc-prolonging activities of Zuclopenthixol.
